Comparative Pharmacology
Head-to-head clinical analysis: DSUVIA versus INFUMORPH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DSUVIA versus INFUMORPH.
DSUVIA vs INFUMORPH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, high-affinity agonist at the mu-opioid receptor, resulting in analgesia via activation of G-protein coupled inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels in the central nervous system.
Morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. It mimics endogenous endorphins by binding to opioid receptors in the CNS, causing inhibition of ascending pain pathways and altering pain perception.
30 mcg sublingual tablet as a single dose; may repeat once after 1 hour if needed. Maximum 2 doses per 24 hours.
Morphine sulfate 10-30 mg orally every 4 hours as needed; or 2.5-15 mg IV/IM/SC every 2-6 hours; or 0.5-2 mg per hour continuous IV infusion. Extended-release formulations: 15-30 mg orally every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 23.4 hours (range 17–30 h), supporting once-daily dosing. Due to rapid redistribution, clinical effects may wane before elimination is complete.
Terminal elimination half-life: 2–4 hours in healthy adults; prolonged to 4–6 hours in the elderly or those with renal impairment, leading to accumulation of active metabolites (M6G).
Primarily renal elimination of metabolites; unchanged drug accounts for <1% of the dose. Fecal excretion is minimal. Total recovery: ~70% in urine, ~20% in feces.
Renal elimination of morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) accounts for approximately 90% of total clearance, with <10% excreted as unchanged morphine in urine. Biliary/fecal elimination accounts for the remaining fraction (<10%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic